Gene and protein markers of diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 23, Issue 3, 2008, Pages 792-799

  Granier, Claude ^a,d   Makni, Kaouthar ^b   Molina, Laurence ^a   Jardin Watelet, Bénédicte ^a   Ayadi, Hammadi ^b   Jarraya, Fayçal ^b,c  

^a CNRS FRE3009 SysDiag   (France)

^b CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^c HEDI CHAKER HOSPITAL   (Tunisia)

^d CNRS FRE3009   (France)

Author keywords

Biomarkers; Candidate genes; Diabetic nephropathy; Diagnostic

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALDEHYDE REDUCTASE; BIOLOGICAL MARKER; COLLAGEN TYPE 4; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE TRANSPORTER 1; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; ADIPONECTIN; BETAIG H3 PROTEIN; BETAIG-H3 PROTEIN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE MARKER; EDITORIAL; GENE INSERTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ALBUMINURIA; GENETICS; URINE;

ADIPONECTIN; ALBUMINURIA; BIOLOGICAL MARKERS; COLLAGEN TYPE IV; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX PROTEINS; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LINKAGE (GENETICS); TRANSFORMING GROWTH FACTOR BETA;

EID: 42449154706     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm834     Document Type: Editorial

References (82)

1. Cameron JS. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol 2006; 19(Suppl 10): S75-S87
2. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25: 971-1010
3. Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int 1991; 40: 792-807
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
5. Gross JL, de Azevedo MJ, Silveiro SP et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176
6. Susztak K, Bottinger EP. Diabetic nephropathy: a frontier for personalized medicine. J Am Soc Nephrol 2006; 17: 361-367
7. Moses R, Rodgers D, Griffiths R. Diabetic control and hypoglycaemia in the Illawarra area of NSW, Australia: a comparison with the DCCT. J Qual Clin Pract 1995; 15: 89-97
8. Fogarty DG, Hanna LS, Wantman M et al. Segregation analysis of urinary albumin excretion in families with type 2 diabetes. Diabetes 2000; 49: 1057-1063
9. Imperatore G, Knowler WC, Pettitt DJ et al. Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes 2000; 49: 1049-1056
10. Boright AP, Paterson AD, Mirea L et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 2005; 54: 1238-1244
11. Jacobsen PK. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). J Renin Angiotensin Aldosterone Syst 2005; 6: 55-68
12. Imperatore G, Hanson RL, Pettitt DJ et al. Pima Diabetes Genes Group. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 1998; 47: 821-830
13. Bowden DW, Colicigno CJ, Langefeld CD et al. A genome scan for diabetic nephropathy in African Americans. Kidney Int 2004; 66: 1517-1526
14. Vardarli I, Baier LJ, Hanson RL et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002; 62: 2176-2183
15. Osterholm AM, He B, Pitkaniemi J et al. Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int 2007; 71: 140-145
16. Moczulski DK, Rogus JJ, Antonellis A et al. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes 1998; 47: 1164-1169
17. Chistiakov DA, Savost'anov KV, Shestakova MV et al. Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23-q24 by association study in Russian type 1 diabetic patients. Diabetes Res Clin Pract 2004; 66: 79-86
18. Penno G, Chaturvedi N, Talmud PJ et al. EURODIAB Controlled Trial of Lisinopril in IDDM. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. Diabetes 1998; 47: 1507-1511
19. Solini A, Dalla Vestra M, Saller A et al. The angiotensin- converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 2002; 51: 251-255
20. Ng DP, Tai BC, Koh D et al. Angiotensin-I-converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 2005; 48: 1008-1016
21. Hadjadj S, Tarnow L, Forsblom C et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 2007; 18: 1284-1291
22. Chung SS, Chung SK. Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 2003; 10: 1375-1387
23. Ko GT, Chow CC, Li CY et al. Insulin-dependent diabetes mellitus presenting as diabetic ketoacidosis in pregnancy. Aust N Z J Obstet Gynaecol 1995; 35: 321-322
24. Moczulski DK, Scott L, Antonellis A et al. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med 2000; 17: 111-118
25. Neamat-Allah M, Feeney SA, Savage DA et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabet Med 2001; 18: 906-914
26. Olmos P, Acosta AM, Schiaffino R et al. Aldose reductase gene polymorphism and rate of appearance of retinopathy in non insulin dependent diabetics. Rev Med Chil 1999; 127: 399-409
27. Shah VO, Scavini M, Nikolic J et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab 1998; 83: 2886-2891
28. Liu YF, Wat NM, Chung SS, et al. Diabetic nephropathy is associated with the 5′-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes. Diabet Med 2002; 19: 113-118
29. Isermann B, Schmidt S, Bierhaus A et al. (CA)(n) dinucleotide repeat polymorphism at the 5′-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1. Nephrol Dial Transplant 2000; 15: 918-920
30. Maeda S, Haneda M, Yasuda H et al. Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes. Diabetes 1999; 48: 420-422
31. Moczulski DK, Burak W, Doria A et al. The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (noninsulin-dependent) diabetes mellitus.Diabetologia 1999; 42: 94-97
32. Hodgkinson AD, Millward BA, Demaine AG. Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy. Kidney Int 2001; 59: 985-989
33. Sivenius K, Niskanen L, Voutilainen-Kaunisto R et al. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes.Diabet Med 2004; 21: 1325-1333
34. Gosek K, Moczulski D, Zukowska-Szczechowska E. C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control. Nephron Exp Nephrol 2005; 99: e63-e67
35. Makiishi T, Araki S, Koya D et al. C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 943-951
36. Orchard TJ, Chang YF, Ferrell RE et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002; 62: 963-970
37. Herrmann SM, Ringel J, Wang JG, et al. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002; 51: 2653-2657
38. Caramori ML, Canani LH, Costa LA, et al. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003; 52: 3010-3013
39. Pollex RL, Mamakeesick M, Zinman B et al. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 2007; 21: 166-171
40. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866
41. Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia 1992; 35: 499-504
42. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997; 46(Suppl 2): S19-S25
43. Gutierrez C, Vendrell J, Pastor R et al. GLUT1 gene polymorphism in non-insulin-dependent diabetes mellitus: genetic susceptibility relationship with cardiovascular risk factors and microangiopathic complications in a Mediterranean population. Diabetes Res Clin Pract 1998; 41: 113-120
44. Tarnow L, Grarup N, Hansen T, et al. Diabetic microvascular complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients. Nephrol Dial Transplant 2001; 16: 1653-1656
45. Liu ZH, Guan TJ, Chen ZH et al. Glucose transporter (GLUT1) allele (XbaI-) associated with nephropathy in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1843-1848
46. Grzeszczak W, Moczulski DK, Zychma M et al. Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes. Kidney Int 2001; 59: 631-636
47. Ng DP, Canani L, Araki S et al. Minor effect of GLUT1 polymorphisms on susceptibility to diabetic nephropathy in type 1 diabetes. Diabetes 2002; 51: 2264-2269
48. Zintzaras E, Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet 2005; 50: 84-91
49. Hodgkinson AD, Page T, Millward BA et al. A novel polymorphism in the 5′ flanking region of the glucose transporter (GLUT1) gene is strongly associated with diabetic nephropathy in patients with Type 1 diabetes mellitus. J Diabetes Complications 2005; 19: 65-69
50. Janssen B, Hohenadel D, Brinkkoetter P et al. Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005; 54: 2320-2327
51. Freedman BI, Hicks PJ, Sale MM et al. A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans.Nephrol Dial Transplant 2007; 22: 1131-1135
52. Group TMCS (the Microalbuminuria Collaborative Study Group). Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 1999; 16: 918-925
53. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-1408
54. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
55. Cordonnier DJ, Pinel N, Barro C et al., the Diabiopsies Group. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253-1263
56. Comper WD, Jerums G, Osicka TM. Differences in urinary albumin detected by four immunoassays and high-performance liquid chromatography. Clin Biochem 2004; 37: 105-111
57. Polkinghorne KR, Su Q, Chadban SJ et al. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis 2006; 47: 604-613
58. Brinkman JW, Bakker SJ, Gansevoort RT et al. Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. Kidney Int Suppl 2004: S69-S75
59. Osicka TM, Comper WD. Characterization of immunochemically nonreactive urinary albumin. Clin Chem 2004; 50: 2286-2291
60. Sviridov D, Meilinger B, Drake SK et al. Coelution of other proteins with albumin during size-exclusion HPLC: implications for analysis of urinary albumin. Clin Chem 2006; 52: 389-397
61. Chan OT, Herold DA. Chip electrophoresis as a method for quantifying total microalbuminuria. Clin Chem 2006; 52: 2141-2146
62. Watanabe H, Sanada H, Shigetomi S et al. Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron 2000; 86: 27-35
63. Tomino Y, Suzuki S, Azushima C et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal 2001; 15: 188-192
64. Inomat S, Haneda M, Moriya T et al. Revised criteria for the early diagnosis of diabetic nephropathy. Nippon Jinzo Gakkai Shi 2005; 47: 767-769
65. Koshimura J, Fujita H, Narita T et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 2004; 316: 165-169
66. Fujita H, Morii T, Koshimura J et al. Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 2006; 53: 745-752
67. Dalla Vestra M, Masiero A, Roiter AM et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52: 1031-1035
68. Nakamura T, Ushiyama C, Suzuki S et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15: 1379-1383
69. Patari A, Forsblom C, Havana M et al. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 2003; 52: 2969-2974
70. Turk N, Mornar A, Mrzljak V et al. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria. Diabetes Metab 2004; 30: 187-192
71. Thomas MC, Forbes JM, MacIsaac R et al. Low-molecular weight advanced glycation end products:markers of tissue AGE accumulation and more? Ann N Y Acad Sci 2005; 1043: 644-654
72. Ha SW, Kim HJ, Bae JS et al. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004; 65: 167-173
73. Cha DR, Kim IS, Kang YS et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Diabet Med 2005; 22: 14-20
74. Sharma K, Lee S, Han S et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005; 5: 2648-2655
75. Jain S, Rajput A, Kumar Y et al. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Physicians India 2005; 53: 513-520
76. Rao PV, Lu X, Standley M et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007; 30: 629-637
77. Meier M, Kaiser T, Herrmann A et al. Identification of urinary protein pattern in Type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005; 19: 223-232
78. Otu HH, Can H, Spentzos D et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007; 30: 638-643
79. Dihazi H, Muller GA, Lindner S et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53: 1636-1645
80. Susztak K, Sharma K, Schiffer M et al. Genomic strategies for diabetic nephropathy. J Am Soc Nephrol 2003; 14: S271-278
81. Thongboonkerd V, McLeish KR, Arthur JM et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002; 62: 1461-1469
82. Adachi J, Kumar C, Zhang Y et al. The human urinary proteome contains more than 1500 proteins including a large proportion of membranes proteins. Genome Biol 2006; 7: R80